Panel Presents Four Templates to Broaden Clinical Trial Accrual

Clinical Trials Advisor
A A
Broadening clinical trials eligibility criteria will require re-assessing approaches and a change in culture, according to a panel of FDA representatives, government scientists, academic researchers and members of the pharmaceutical industry.

To View This Article:

Login

Subscribe To Clinical Trials Advisor